3
Announcements
Trials
Browse
Landscape
Status
Completed
19
Terminated
5
Active not recruiting
3
Unknown
2
Withdrawn
1
Recruiting
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Recurrence
9
Neoplasms
6
Multiple Myeloma
6
Breast Neoplasms
6
Small Cell Lung Carcinoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
HER2-positive Breast Cancer
3
Glioma
3
Carcinoma, Medullary
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Waldenstrom Macroglobulinemia
1
Urogenital Neoplasms
1
Tumors Harboring NTRK Fusion
1
Interventions
vorasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing